Intra-arterial versus Intravenous Cisplatinum (in Addition to Systemic Adriamycin and High Dose Methotrexate) in the Neoadjuvant Treatment of Osteosarcoma of the Extremities. Results of a Randomized Study
Authors: Bacci, G.; Ruggieri, P.; Picci, P.; Mercuri, M.; Ferraro, A.; Tella, G.; Ferrari, S.; Bertoni, F.; Comandone, A.
Source: Journal of Chemotherapy, Number 1, February 1996 , pp. 70-81(12)
Publisher: Maney Publishing
Abstract:Intra-arterial (IA) and intravenous (IV) cisplatinum (CDP) were studied in a multiagent regimen of neoadjuvant chemotherapy for osteosarcoma of the extremities. Preoperatively two cycles of high-dose methotrexate (HDMTX) were administered, followed 5 days later by CDP and Adriamycin (ADM). MTX and ADM were administered IV, and CDP was delivered IA or IV. Postoperatively, good responders received 3 more cycles of the same drugs, while poor responders had a longer chemotherapy including ifosfamide.
The rate of good histological response to chemotherapy was significantly higher in patients treated intra-arte-rially (78% vs 46%: P < .004), while no significant differences in terms of disease-free survival were observed between patients who received CDP IA and patients who received CDP IV (55% vs 51%). In the IA group, however, there was only one local recurrence vs 5 in the IV group.
The IA infusion of CDP is more active on the primary tumor than the IV infusion.
Document Type: Research Article
Publication date: 1996-01-01